Tech Company Financing Transactions
Inipharm Funding Round
On 11/12/2020, Inipharm announced $35 million in Series A funding from 5AM Ventures, Frazier Healthcare Partners and Jubilant Biosys.
Transaction Overview
Company Name
Announced On
11/12/2020
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series A
Investors
Proceeds Purpose
The Series A funding will support the advancement of Inipharm's lead program through IND filing and into clinical trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
500 108th Ave. NE 1100
Bellevue, WA 98004
USA
Bellevue, WA 98004
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Highly Validated Approaches to Highly Unmet Need. Developing Treatments for Severe Liver Disease. At Inipharm, we're building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm's lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for liver and related diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brian Farmer
Chief Scientific Officer
Heather Hsu
Vice President
Vince Florio
Vice President
Joshua Odingo
Browse more venture capital transactions:
Prev: 11/12/2020: Thoughtexchange venture capital transaction
Next: 11/12/2020: Trailhead Biosystems venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs